Codexis presented new data showing its ECO Synthesis® platform achieves over 90% product quality and nearly halves cycle time at a 100-gram manufacturing scale, maintaining consistent performance across scales. The platform also demonstrated enhanced siRNA potency through stereochemical control, with a 3- to 4-fold increase in biological efficacy compared to traditional methods. These advances support Codexis' progress toward industrial-scale, cost-effective production of RNA therapeutics with improved targeting and precision. The company aims to meet growing demand for RNAi drugs with scalable, efficient enzymatic manufacturing.
Codexis' advances in ECO Synthesis and siRNA manufacturing come as a backdrop to health-sector market activity on Pluang. For readers following health stocks, 100 of 150 priced US health-sector stocks rose while 26 fell as of Nov 09, 2026 17:41 WIB. Notable movers include HRTX at USD 0.29 with a 2.99% increase and a typical hold time of 39 days, CTXR at USD 0.54 down 2.98%, and MDLN at USD 38.65 down 2.50%.
Claritev Corporation reported Q3 2026 revenues of $268.3 million, up 9.1% from the previous year, with adjusted EBITDA increasing 4.4% to $162 million. Despite a net loss of $61.8 million, the company highlighted strong growth across its solutions an...
India's quick commerce market is projected to grow from $3.65 billion in 2026 to $7.39 billion by 2032, expanding at a 12.41% CAGR. Growth is fueled by rising smartphone and internet penetration, expanding dark-store networks, and increasing demand f...
Payments Canada has launched the Real-Time Rail (RTR), a new national payment system enabling instant, 24/7 payment clearing and settlement for Canadian businesses and consumers. This modern infrastructure supports real-time cash flow visibility, dat...
Mana Battery has appointed Dr. Frederik Morgenstern, former BMW battery innovation lead, as VP of Cell Engineering. Morgenstern brings extensive experience in developing high-performance battery cells, including BMW's 6th-generation cylindrical cell,...
ISS A/S is actively executing its share buyback program announced in February 2026, aiming to redistribute excess cash to shareholders and reduce share capital. As of early November 2026, the company has repurchased approximately 7.69 million shares ...
